Clearmind Medicine is assessing its lead drug candidate CMND-100 (MEAI), a non-hallucinogenic psychedelic treatment for Alcohol Use Disorder, for eligibility for the FDA's Breakthrough Therapy Designation. This designation could accelerate approval due to positive Phase I/IIa clinical trial results and recent supportive FDA policies. Alcohol Use Disorder is a serious condition with limited effective treatments, making this potential designation significant for patient care. The company has not yet submitted the formal request to the FDA but remains committed to advancing this therapy.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
Standard Chartered has partnered with Broadcom to modernize its global banking infrastructure by adopting a secure, resilient private cloud using VMware Cloud Foundation. This upgrade supports critical banking services across 54 markets with enhanced...
